Group items tagged

As we take look back over the past year and reflect on what we have achieved, it's also important that we look ahead to new challenges and opportunities that may arise in 2023. We have seen remarkable innovation across the industry in 2022, from big break throughs in treatment and improvements to patient outcomes, to how the industry is working with big data and technology. But it's fair to say that these achievements came paired with just as many challenges including a continued talent shortage, hangovers from the pandemic, increasing pressures to innovate and ongoing macroeconomic challenges. As we head into 2023, I expect these existing challenges to continue alongside new ones, but I also anticipate more opportunities to present themselves. At Pharamanovia, we predict that the key trends set to catalyse the pharmaceutical and healthcare industries in 2023 include break through innovations, technology, big data, sustainability, ongoing policy changes and a shift in investment due to inflation. Utilising big data and tech Technology has been recognised as one of the industry's biggest tools for many years, and I don't expect to see the pace of how we use technology in healthcare and pharma to slow down any time soon. In 2023, I expect that we will see further automation in the way we work, with an increase in digital engagement and healthcare providers leveraging remote access further.

The UK pharmaceutical industry experienced a substantial increase in public trust and favourability during the Covid-19 pandemic, according to a new poll. This trend appears to be persisting with the study showing a generally favourable view of the sector. The recent survey, conducted by Ipsos and commissioned by Association of the British Pharmaceutical Industry (ABPI), represents the third instalment in a series that began in 2021. This ongoing study targets members of the public, healthcare professionals, and parliamentarians. The study once again underscored a favourable perception of the sector with 67 per cent of respondents recognising that the pharmaceutical industry produces safe and effective medicines using cutting-edge technologies. Moreover, a majority agrees that it is a highly innovative field. Seven out of 10 people also trust the sector's readiness to address future pandemics, even as media attention on pharmaceutical companies returns to pre-pandemic levels. However, concerns arise regarding limitations in accessing new medicines due to cost pressures.

In a rapidly evolving and competitive landscape, the pharmaceutical industry faces unique challenges when it comes to marketing its products and services. With stringent regulations, complex target audiences, and a need for trust and credibility, pharma companies need to employ effective marketing strategies to stand out in the crowd. In this blog article, we will explore some key marketing strategies for the pharma industry that can help boost their visibility, engage their target audience, and drive business growth. UNDERSTANDING THE UNIQUE LANDSCAPE The pharma industry operates in a highly regulated environment, where compliance and ethical considerations play a crucial role. Before diving into marketing strategies, it is essential to have a deep understanding of the industry's dynamics and the target audience. Researching the market, identifying patient needs, and studying the competitive landscape are vital steps in developing an effective marketing plan. EMBRACING DIGITAL TRANSFORMATION Digital transformation has revolutionized marketing across industries, and the pharma sector is no exception. Embracing digital channels and technologies can significantly enhance the reach and impact of marketing efforts. Pharma companies can leverage social media platforms, create engaging content, and build online communities to connect with patients, healthcare professionals, and other stakeholders. Implementing robust digital marketing strategies allows for personalized messaging, real-time communication, and targeted campaigns that resonate with the target audience.

The Association of the British Pharmaceutical Industry (ABPI) has appointed Susan Rienow, country president of Pfizer, as its vice president. "As vice president, she will support the president, Pinder Sahota, general manager and corporate vice president of Novo Nordisk UK, in delivering his priorities. These are improving access to medicines, delivering economic growth and helping to find solutions to big societal challenges such as climate change, AMR, and inequalities," said ABPI in a statement. At Pfizer, Susan leads the organisation to bring the power of innovation, data and technology together to transform healthcare and improve outcomes for patients. She previously led Pfizer UK's vaccines business unit during the Covid-19 pandemic.

Throughout the past decade, digital transformation has been at the forefront of the agenda for the NHS which has been accelerated by the abundance of digitally enabled ways of working during the pandemic. While the last year has unquestionably heralded the spring shoots of transformation, there is so much to be done to build upon this and accelerate further. For example, do both pharmacists and patients comprehend the value of digital to drive change at a fundamental level? The issue is not simply ensuring that the temporary fixes inspired by the pandemic successfully transition to standard practice, but also rapidly building on that foundation to enable the greatest value from digitisation within pharmacy. Covid-19 has increased the need for digitally enabled and empowered ways of operating. From the backlog in outpatient appointments to postponed screening programmes and, crucially, the potential exodus of overworked and stressed pharmacists, the efficient, effective and intelligent care enabled by the right digital technologies is now critical.